Edesa Biotech reports 2022 EPS ($1.05) vs. ($1.10) last year

"We believe the significant strides we made in 2022 have positioned us for continued and accelerated progress," said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. "With two late-stage studies, a growing development pipeline, large addressable markets and interest from potential partners, we are excited about the opportunities we are bringing into the new year."